Pomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.
CLPT
ClearPoint Neuro, Inc. · NASDAQ
Sign up free to see this.
Mkt Cap
$278.9M
Volume
297K
52W High
$27.27
52W Low
$8.27
PE Ratio
—
Avg Vol
701.3K
As of 10/23/26
Div Yield
—
Beta
1.75
As of 10/23/26
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Sentiment
No sentiment yet
At least 5 tagged posts are needed.
How do you feel about CLPT?
Latest news
News ›Headlines link to the publisher. Not investment advice.
Board · 0 threads
Open board ›No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Community
7 daysNo sentiment yet
Posts 24h
0
Replies 24h
0
Watchers
0
Board · $CLPT · 0 threads
Sign in to post on $CLPT
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.